Hat-Hdac System In Asthma

Xiaoru Sun,Zhihong Chen,Xiangdong Wang

DOI: https://doi.org/10.1007/978-981-10-8764-6_12

2018-01-01

Abstract:Diverse biological processes, including regulation of inflammatory gene expression, DNA damage repair, and cell growth, are balanced by modifications on histones such as acetylation (HAT) and deacetylation (HDAC). HAT/HDAC has recently emerged as a critical regulator of inflammatory disease.HATs are enzymes that specifically add an acetyl group to the lysine amino acids within a conserved motif on histone proteins resulting in loosening the DNA from histones, and driving inflammatory gene expression. HDACs, grouped in four classes, suppress the inflammatory gene expression by reversing the reaction catalyzed by HATs.The chapter is focusing on the potential asthma-relief effects of HAT and/or HDAC compounds. Recently, more specific HAT inhibitors (HATi) and HDAC inhibitors (HDACi) have been described. This can now serve as perfect tools to study the function of HATs and HDACs in model systems of asthma. Oral or inhaled corticosteroids are widely used as maintenance therapy for asthmatics. However, its disease control effect is diminished in asthma smokers and severe asthma patients. Reduced responsiveness to the anti-inflammatory effects of corticosteroids is a major barrier to effective management of asthma in smokers and patients with severe asthma. Reduced expression of HDAC2 may be involved in the molecular mechanism of corticosteroid insensitivity in asthmatics. We further investigate how HDAC2 play a role in glucocorticoid (GC) insensitivity in asthmatics and find it is a potential target to reverse GC activity.Although the precise mechanisms of HAT/HDAC are still controversial, their roles as potential drug targets for asthma have been represented. It should also be noted the existence of multiple subtypes of HDAC/HAT adds to the complexity of their biological effect in asthma. This remains a hot area in today's asthma research.